Filtered By:
Infectious Disease: Hepatitis B

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 149 results found since Jan 2013.

5'-triphosphate-siRNA activates RIG-I-dependent type I interferon production and enhances inhibition of hepatitis B virus replication in HepG2.2.15 cells.
In conclusion, our findings suggest that 3p-siRNA could act as a powerful bifunctional antiviral molecule with potential for developing a promising therapeutic against chronic HBV infection. PMID: 24099962 [PubMed - as supplied by publisher]
Source: European Journal of Pharmacology - October 4, 2013 Category: Drugs & Pharmacology Authors: Chen X, Qian Y, Yan F, Tu J, Yang X, Xing Y, Chen Z Tags: Eur J Pharmacol Source Type: research

Targeted Delivery of siRNA against Hepatitis B Virus by PreS1 Peptide Molecular Ligand
ConclusionThe results indicated that PreS1‐9Arg may be a potential novel vector to deliver siRNA targeting liver cells.
Source: Hepatology Research - June 28, 2013 Category: Internal Medicine Authors: Wenjuan Huang, Xia Li, Min Yi, Sufen Zhu, Weixian Chen Tags: Original Article Source Type: research

Hepatic Stellate Cells in Liver Fibrosis and siRNA-Based Therapy.
Abstract Hepatic fibrosis is a reversible wound-healing response to either acute or chronic liver injury caused by hepatitis B or C, alcohol, and toxic agents. Hepatic fibrosis is characterized by excessive accumulation and reduced degradation of extracellular matrix (ECM). Excessive accumulation of ECM alters the hepatic architecture leading to liver fibrosis and cirrhosis. Cirrhosis results in failure of common functions of the liver. Hepatic stellate cells (HSC) play a major role in the development of liver fibrosis as HSC are the main source of the excessive production of ECM in an injured liver. RNA interfere...
Source: Pharmacological Reviews - August 17, 2016 Category: Drugs & Pharmacology Authors: Omar R, Yang J, Liu H, Davies NM, Gong Y Tags: Rev Physiol Biochem Pharmacol Source Type: research

Targeting cancer cell-specific RNA interference by siRNA delivery using a complex carrier of affibody-displaying bio-nanocapsules and liposomes
Conclusions: These findings show that, in the field of nucleic acid medicine, ZHER2-BNC/LP can be a useful carrier for siRNA delivery, and could also become a useful tool for gene silencing and to accomplish protein knock-down.
Source: Journal of Nanobiotechnology - June 24, 2013 Category: Nanotechnology Authors: Yuya NishimuraHiroaki MiedaJun IshiiChiaki OginoToshinobu FujiwaraAkihiko Kondo Source Type: research

siRNA nanotherapeutics: a promising strategy for anti-HBV therapy
Chronic hepatitis B (CHB) is the most common cause of hepatocellular carcinoma (HCC) and liver cirrhosis worldwide. In spite of the numerous advances in the treatment of CHB, drugs and vaccines have failed because of many factors like complexity, resistance, toxicity, and heavy cost. New RNA interference (RNAi)-based technologies have developed innovative strategies to target Achilles' heel of the several hazardous diseases involving cancer, some genetic disease, autoimmune illnesses, and viral disorders particularly hepatitis B virus (HBV) infections. Naked siRNA delivery has serious challenges including failure to cross ...
Source: IET Nanobiotechnology - June 21, 2019 Category: Nanotechnology Source Type: research

PreS/2-21-Guided siRNA Nanoparticles Target to Inhibit Hepatitis B Virus Infection and Replication
A viable therapy is needed to overcome the deadlock of the incurable chronic hepatitis B (CHB). The prolonged existence of covalently closed circular DNA (cccDNA) and integrated HBV DNA in the nucleus of hepatocytes is the root cause of CHB. As a result, it is critical to successfully suppress HBV DNA replication and eliminate cccDNA. RNA interference has been proven in recent research to silence the expression of target genes and thereby decrease HBV replication. However, siRNA is susceptible to be degraded by RNA enzymes in vivo, making it difficult to deliver successfully and lacking of tissue targeting. To exploit the ...
Source: Frontiers in Immunology - April 29, 2022 Category: Allergy & Immunology Source Type: research

SiRNA-targeted carboxypeptidase D inhibits hepatocellular carcinoma growth.
Abstract Carboxypeptidase D (CPD), a membrane-bound metallocarboxypeptidase that functions as a docking receptor for duck hepatitis B virus, is frequently overexpressed in human cancers. We have explored its expression pattern, clinical significance, and biological function of CPD in hepatocellular carcinoma (HCC). CPD expression was markedly elevated in HCCs relative to adjacent non-tumor liver tissues, as determined by quantitative real-time polymerase chain reaction and Western blot analysis. Immunohistochemistry showed that 164 of 400 (41%) HCCs had high expression of CPD. CPD overexpression was significantly ...
Source: Cell Biology International - April 16, 2013 Category: Cytology Authors: Jin T, Fu J, Feng XJ, Wang SM, Huang X, Zhu MH, Zhang SH Tags: Cell Biol Int Source Type: research

5'-triphosphate siRNA targeting HBx elicits a potent anti-HBV immune response in pAAV-HBV transfected mice.
Abstract RNA with 5'-triphosphate (3p-RNA) is recognized by RNA sensor RIG-I (retinoic acid-inducible gene I protein). Previously, we reported that small interfering RNA targeting HBx (3p-siHBx) could confer potent anti-hepatitis B virus (HBV) efficacy via HBx silencing and RIG-I activation. However, the characteristics of innate and adaptive immunity especially exhaustion profiles in the liver microenvironment in response to 3p-siHBx therapy have not been fully elucidated. Here, we observed that 3p-siHBx more significantly inhibited HBV replication in vivo. 3p-siHBx enhanced natural killer (NK) cell activation wi...
Source: Antiviral Research - November 15, 2018 Category: Virology Authors: Han Q, Hou Z, Yin C, Zhang C, Zhang J Tags: Antiviral Res Source Type: research

Endothelial Cell-Derived TGF- β Promotes Epithelial-Mesenchymal Transition via CD133 in HBx-Infected Hepatoma Cells
Conclusion: The study indicates that secretory factors like TGF-β from neighboring endothelial cells may enhance expression of CD133 and impart an aggressive EMT phenotype to HBx-infected hepatoma cells in HBV induced HCC. Introduction Hepatocellular Carcinoma (HCC) is one of the most common cancer worldwide, representing approximately 4% of all malignancies (1). It has been estimated that more than 50% of HCC cases in the world are associated with hepatitis B virus (HBV) (2). HBV is a partially double stranded DNA virus belonging to the Hepadnavirus family. The HBV genome is 3.2 kb in size and contains fou...
Source: Frontiers in Oncology - April 23, 2019 Category: Cancer & Oncology Source Type: research

IFIT5 Participates in the Antiviral Mechanisms of Rainbow Trout Red Blood Cells
We described a new defense mechanism based on IFIT5 antiviral activity in nucleated RBCs that appeared to contribute to halting the VHSV infection. This finding sheds light into novel antiviral therapeutics to mitigate the economic losses and social impact caused by viral infections in the aquaculture industry. This work broadens the knowledge of fish nucleated RBCs functions and their role in the immune response to viral infections. Ethics Statement Experimental protocols and methods relating to experimental animals were reviewed and approved by the Animal Welfare Body and the Research Ethics Committee at the University...
Source: Frontiers in Immunology - April 15, 2019 Category: Allergy & Immunology Source Type: research

Hepatitis B virus X protein boosts hepatocellular carcinoma progression by downregulating microRNA-137.
CONCLUSION: Overexpression of miR-137 blocks HCC cell proliferation in HBx-siRNA-treated MHCC97H cells by targeting Notch1. This study may offer novel target for HCC treatment. PMID: 32527447 [PubMed - in process]
Source: Pathology, Research and Practice - May 31, 2020 Category: Pathology Authors: Gao Y, Gu J, Wang Y, Fu D, Zhang W, Zheng G, Wang X Tags: Pathol Res Pract Source Type: research

TLR4 Influences Hepatitis B Virus Related Hepatocellular Carcinoma by Regulating the Wnt/ β-Catenin Pathway
Conclusions: TLR4 can affect the expression of β-catenin and hence influence the progression of HBV-related HCC.Cell Physiol Biochem 2017;42:469 –479
Source: Cellular Physiology and Biochemistry - June 2, 2017 Category: Cytology Source Type: research

Inhibition of hepatitis B virus (HBV) gene expression and replication by HBx gene silencing in a hydrodynamic injection mouse model with a new clone of HBV genotype B
Conclusions: Taken together, the HI mouse model with a HBV genotype B genome was successfully established and showed different characteristics in vivo compared with the genotype A genome. The effectiveness of gene silencing against HBx gene determines whether HBV replication may be sustainably inhibited by siRNA in vivo.
Source: Virology Journal - June 28, 2013 Category: Virology Authors: Lei LiHong ShenAnyi LiZhenhua ZhangBaoju WangJunzhong WangXin ZhengJun WuDongliang YangMengji LuJingjiao Song Source Type: research

HBxAg suppresses cell apoptosis and promotes the secretion of placental hormones in human placental trophoblasts via activation of the EGFR/Akt pathway.
In conclusion, the pEGFR protein was robustly upregulated in HBx-infected human placenta tissues and trophoblast cells. HBx reduces cell apoptosis and promotes the secretion of placental hormones in human placental trophoblast cells via activation of the EGFR/Akt pathway. PMID: 29052908 [PubMed - as supplied by publisher]
Source: Cell Biology International - October 20, 2017 Category: Cytology Authors: Wang W, Bai G, Zhang Y, Zhang T, Li C, Yuan Y, Liu S, Wang C Tags: Cell Biol Int Source Type: research

CRTC2 enhances HBV transcription and replication by inducing PGC1alpha expression
Conclusions: Our results clearly indicate that non-phosphorylated CRTC2 strongly enhances HBV biosynthesis through inducing PGC1alpha expression. Further study of the mechanisms will elucidate the importance of metabolic signals on HBV transcription and replication, and offer insight into potential targets for developing anti-HBV agents.
Source: Epidemiologic Perspectives and Innovations - February 14, 2014 Category: Epidemiology Authors: Xiaohui TianFei ZhaoWeihua SunXiaoguang ZhiZhikui ChengMing ZhouKanghong Hu Source Type: research